Abstract MP43: Baseline High-Sensitivity Cardiac Troponin-T is Independently Associated With Incident Hypertension
Introduction: Elevated blood pressure (BP) is often preceded by cardiac structural abnormalities, potentially allowing early detection before the onset of overt hypertension.
Hypothesis: We hypothesized that high-sensitivity cardiac troponin-T (hs-cTNT), a marker of subclinical myocardial damage, can identify persons at risk for hypertension.
Methods: We studied 6,516 ARIC Study participants, free of prevalent hypertension and cardiovascular disease at baseline (1990-1992). Using Cox models, we examined the association of baseline hs-cTNT categories with incident diagnosed hypertension (defined by medication use or annual self-report over a median of 12 years) and with incident visit-based hypertension (defined by medication use, self-report, or BP measurement [>140/90 mmHg] over 6 years).
Results: Relative to hs-cTNT <5ng/L, adjusted hazard-ratios for incident diagnosed hypertension were 1.16 (95% CI 1.08, 1.25) for those with hs-cTNT 5-8ng/L, 1.29 (1.14, 1.47) for hs-cTNT 9-13ng/L, and 1.31 (1.07, 1.61) for hs-cTNT ≥14ng/L (p-value for trend <0.001). Findings were stronger for incident visit-based hypertension. We noted higher relative hazard in normotensive persons (relative to those with prehypertension). Associations were not appreciably changed after adjustment for baseline NT-proBNP. In addition, baseline hs-cTNT was associated with a combined outcome of incident hypertension or incident LVH over 6 years follow-up (adjusted hazard-ratio of 1.58 [1.16-2.15], comparing hs-cTNT ≥14ng/L vs <5ng/L).
Conclusion: In conclusion, baseline hs-cTNT is associated with incident hypertension and risk of LVH. Further research is needed to determine whether hs-cTNT can identify persons who may benefit from ambulatory BP monitoring, hypertension prevention lifestyle strategies, or early BP intervention.
Author Disclosures: B. Mcevoy: C. Other Research Support; Modest; Reagents for the high-sensitivity cardiac troponin-T and C-reactive protein assays were donated by Roche Diagnostics.. Y. Chen: None. V. Nambi: F. Ownership Interest; Modest; Drs. Ballantyne and Nambi are co-investigators on a provisional patent filed by Roche for use of biomarkers in heart failure prediction. C. Ballantyne: B. Research Grant; Modest; Dr Ballantyne has received grant support from Roche Diagnostics (and the National Institutes of Health).. F. Ownership Interest; Modest; Drs. Ballantyne and Nambi are co-investigators on a provisional patent filed by Roche for use of biomarkers in heart failure prediction.. R. Sharrett: None. L. Appel: None. W. Post: None. R. Blumenthal: None. K. Matsushita: E. Honoraria; Modest; Dr. Matsushita has received an honorarium from Mitsubishi Tanabe Pharma, Kyowa Hakko Kirin, and Merck Sharp & Dohme.. E. Selvin: None.
- © 2015 by American Heart Association, Inc.